{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T16:54:34Z","timestamp":1769878474433,"version":"3.49.0"},"reference-count":26,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T00:00:00Z","timestamp":1591056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Toxins"],"abstract":"<jats:p>This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively, p = 0.085) at week three. Among the 33 patients with detrusor overactivity (DO), patients who received BoNT-A had a higher cure rate of incontinence (88% vs. 41%, p = 0.01) and less required antimuscarinic agent or beta-3 agonist (31% vs. 94%, p &lt; 0.001) compared to patients who did not receive BoNT-A injection. There was no significant difference in the incidences of adverse events between two groups. BoNT-A injection with MUS demonstrated efficacy and safety in the treatment of mixed urinary incontinence, specifically for women with DO.<\/jats:p>","DOI":"10.3390\/toxins12060365","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T04:12:09Z","timestamp":1591157529000},"page":"365","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients"],"prefix":"10.3390","volume":"12","author":[{"given":"Yi-Huei","family":"Chang","sequence":"first","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung 40447, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung 40402, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-7876","authenticated-orcid":false,"given":"Po-Jen","family":"Hsiao","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung 40447, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung 40402, Taiwan"},{"name":"Department of Urology, China Medical University Hsinchu Hospital, Hsinchu 302056, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huang","family":"Chi-Ping","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung 40447, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung 40402, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hsi-Chin","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung 40447, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung 40402, Taiwan"},{"name":"Department of Urology, China Medical University Beigang Hospital, Beigang, Yunlin 651012, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Po-Fan","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung 40447, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung 40402, Taiwan"},{"name":"Graduate Institute of Biomedical Sciences, School of Medicine, China Medical University, Taichung 40402, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric Chieh-Lung","family":"Chou","sequence":"additional","affiliation":[{"name":"Department of Urology, China Medical University Hospital, Taichung 40447, Taiwan"},{"name":"School of Medicine, China Medical University, Taichung 40402, Taiwan"},{"name":"Department of Urology, China Medical University Beigang Hospital, Beigang, Yunlin 651012, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,6,2]]},"reference":[{"key":"ref_1","first-page":"S3","article-title":"The Definition, Prevalence, and Risk Factors for Stress Urinary Incontinence","volume":"6","author":"Luber","year":"2004","journal-title":"Rev. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.eururo.2013.04.001","article-title":"OnabotulinumtoxinA 100 U Significantly Improves All Idiopathic Overactive Bladder Symptoms and Quality of Life in Patients with Overactive Bladder and Urinary Incontinence: A Randomised, Double-Blind, Placebo-Controlled Trial","volume":"64","author":"Chapple","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.eururo.2012.03.005","article-title":"OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial","volume":"62","author":"Fowler","year":"2012","journal-title":"Eur. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1111\/ijcp.12443","article-title":"OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder","volume":"68","author":"Sievert","year":"2014","journal-title":"Int. J. Clin. Pr."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1016\/j.juro.2012.12.022","article-title":"OnabotulinumtoxinA for the Treatment of Patients with Overactive Bladder and Urinary Incontinence: Results of a Phase 3, Randomized, Placebo Controlled Trial","volume":"189","author":"Nitti","year":"2013","journal-title":"J. Urol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1002\/nau.20922","article-title":"Mixed incontinence: Comparing definitions in non-surgical patients","volume":"30","author":"Brubaker","year":"2011","journal-title":"Neurourol. Urodyn."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"373","DOI":"10.4111\/icu.2019.60.5.373","article-title":"De novo or resolved urgency and urgency urinary incontinence after midurethral sling operations: How can we properly counsel our patients?","volume":"60","author":"Shin","year":"2019","journal-title":"Investig. Clin. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/(SICI)1520-6777(2000)19:2<127::AID-NAU3>3.0.CO;2-K","article-title":"A simplified urinary incontinence score for the evaluation of treatment outcomes","volume":"19","author":"Groutz","year":"2000","journal-title":"Neurourol. Urodyn."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1046\/j.1464-410x.1999.00121.x","article-title":"Bladder outlet obstruction index, bladder contractility index and bladder voiding efficiency: three simple indices to define bladder voiding function","volume":"84","author":"Abrams","year":"1999","journal-title":"BJU Int."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/j.eururo.2006.09.019","article-title":"Population-Based Survey of Urinary Incontinence, Overactive Bladder, and Other Lower Urinary Tract Symptoms in Five Countries: Results of the EPIC Study","volume":"50","author":"Irwin","year":"2006","journal-title":"Eur. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s00192-006-0188-5","article-title":"Quality of life in women with stress urinary incontinence","volume":"18","author":"Tennstedt","year":"2006","journal-title":"Int. Urogynecol. J. Pelvic Floor Dysfunct."},{"key":"ref_12","first-page":"S6","article-title":"Stress urinary incontinence in the gynecological practice","volume":"86","author":"Ortiz","year":"2004","journal-title":"Int. J. Gynecol. Obstet."},{"key":"ref_13","first-page":"CD006375","article-title":"Mid-urethral sling operations for stress urinary incontinence in women","volume":"7","author":"Rogerson","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ajog.2016.04.018","article-title":"Midurethral slings: evidence-based medicine vs the medicolegal system","volume":"214","author":"Nager","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.juro.2015.01.087","article-title":"Diagnosis and Treatment of Overactive Bladder (Non-Neurogenic) in Adults: AUA\/SUFU Guideline Amendment","volume":"193","author":"Gormley","year":"2015","journal-title":"J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00192-011-1511-3","article-title":"Prevalence of urinary urgency symptoms decreases by mid-urethral sling procedures for treatment of stress incontinence","volume":"22","author":"Palva","year":"2011","journal-title":"Int. Urogynecol. J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ejogrb.2012.08.011","article-title":"Complications of synthetic slings used in female stress urinary incontinence and applicability of the new IUGA-ICS classification","volume":"165","author":"Petri","year":"2012","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Boil."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1007\/s11255-015-1125-7","article-title":"The safety and efficiency of onabotulinumtoxinA for the treatment of overactive bladder: a systematic review and meta-analysis","volume":"47","author":"Sun","year":"2015","journal-title":"Int. Urol. Nephrol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.eururo.2010.09.007","article-title":"Adverse Events of Intravesical Botulinum Toxin A Injections for Idiopathic Detrusor Overactivity: Risk Factors and Influence on Treatment Outcome","volume":"58","author":"Kuo","year":"2010","journal-title":"Eur. Urol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.juro.2010.08.021","article-title":"Efficacy and Safety of OnabotulinumtoxinA for Idiopathic Overactive Bladder: A Double-Blind, Placebo Controlled, Randomized, Dose Ranging Trial","volume":"184","author":"Dmochowski","year":"2010","journal-title":"J. Urol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1001\/jama.2017.12137","article-title":"Urinary Incontinence in Women","volume":"318","author":"Lukacz","year":"2017","journal-title":"JAMA"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Riemsma, R., Hagen, S., Kirschner-Hermanns, R., Norton, C., Wijk, H., Andersson, K.-E., Chapple, C., Spinks, J., Wagg, A., and Hutt, E. (2017). Can incontinence be cured? A systematic review of cure rates. BMC Med., 15.","DOI":"10.1186\/s12916-017-0828-2"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.eururo.2016.02.030","article-title":"Efficacy and Safety of Mirabegron Add-on Therapy to Solifenacin in Incontinent Overactive Bladder Patients with an Inadequate Response to Initial 4-Week Solifenacin Monotherapy: A Randomised Double-blind Multicentre Phase 3B Study (BESIDE)","volume":"70","author":"Drake","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/j.juro.2016.03.174","article-title":"Mirabegron as Add-On Treatment to Solifenacin in Patients with Incontinent Overactive Bladder and an Inadequate Response to Solifenacin Monotherapy","volume":"196","author":"MacDiarmid","year":"2016","journal-title":"J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3109\/13697137.2015.1090859","article-title":"Female urinary stress incontinence","volume":"18","author":"Cervigni","year":"2015","journal-title":"Climacteric"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1002\/nau.23768","article-title":"Fundamentals of terminology in lower urinary tract function","volume":"37","author":"Drake","year":"2018","journal-title":"Neurourol. Urodyn."}],"container-title":["Toxins"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/6\/365\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:34:56Z","timestamp":1760175296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6651\/12\/6\/365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,2]]},"references-count":26,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,6]]}},"alternative-id":["toxins12060365"],"URL":"https:\/\/doi.org\/10.3390\/toxins12060365","relation":{},"ISSN":["2072-6651"],"issn-type":[{"value":"2072-6651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,2]]}}}